Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
- PMID: 19375664
- DOI: 10.1016/S1474-4422(09)70068-7
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Abstract
Several studies, including work from the Parkinson's disease (PD) non-motor group and others, have established that the non-motor symptoms of PD are common, occur across all stages of PD, are under-reported, and are a key determinant of quality of life. Research suggests that the non-motor symptoms of the disease are frequently unrecognised by clinicians and remain untreated. Even when identified, there is a common perception that many of these symptoms are untreatable. The role of dopaminergic drugs in treating the various non-motor problems of PD, although clinically recognised, has received little attention. In this Review, we investigate the dopaminergic basis of the range of non-motor symptoms that occur in PD such as depression, apathy, sleep disorders (including rapid-eye movement sleep behaviour disorder), and erectile dysfunction. We discuss the evidence that these symptoms are treatable, at least in part, with various dopaminergic strategies and, where relevant, we also refer to the use of deep-brain stimulation of appropriate targets in the brain. This Review provides a comprehensive overview of the management of this challenging aspect of PD.
Similar articles
-
[Non-motor disorders in Parkinson's disease].Rev Neurol. 2008 Sep 1-15;47(5):261-70. Rev Neurol. 2008. PMID: 18780273 Review. Spanish.
-
[Urinary disorders, sexual dysfunction and hypersexuality in Parkinson's disease].Rev Neurol. 2010 Feb 8;50 Suppl 2:S27-31. Rev Neurol. 2010. PMID: 20205139 Review. Spanish.
-
[Dopaminergic stimulation in the non-motor symptoms of Parkinson's disease].Rev Neurol. 2010 Feb 8;50 Suppl 2:S85-94. Rev Neurol. 2010. PMID: 20205148 Review. Spanish.
-
Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease.Am J Geriatr Pharmacother. 2010 Aug;8(4):294-315. doi: 10.1016/j.amjopharm.2010.08.002. Am J Geriatr Pharmacother. 2010. PMID: 20869620 Review.
-
[Sleep disturbances in Parkinson's disease: characteristics, evaluation and therapeutic approaches].Orv Hetil. 2015 Jul 5;156(27):1091-9. doi: 10.1556/650.2015.30191. Orv Hetil. 2015. PMID: 26122904 Review. Hungarian.
Cited by
-
A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2.Front Mol Neurosci. 2020 Aug 27;13:153. doi: 10.3389/fnmol.2020.00153. eCollection 2020. Front Mol Neurosci. 2020. PMID: 32973447 Free PMC article. Review.
-
D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice.Acta Pharmacol Sin. 2021 Feb;42(2):189-198. doi: 10.1038/s41401-020-0433-3. Epub 2020 Jul 21. Acta Pharmacol Sin. 2021. PMID: 32694753 Free PMC article.
-
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease.Transl Neurodegener. 2016 Jun 30;5:12. doi: 10.1186/s40035-016-0059-z. eCollection 2016. Transl Neurodegener. 2016. PMID: 27366321 Free PMC article. Review.
-
Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects.Parkinsons Dis. 2012;2012:198316. doi: 10.1155/2012/198316. Epub 2012 Jul 25. Parkinsons Dis. 2012. PMID: 22888466 Free PMC article.
-
Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease.Mov Disord Clin Pract. 2022 Aug 18;9(7):961-966. doi: 10.1002/mdc3.13533. eCollection 2022 Oct. Mov Disord Clin Pract. 2022. PMID: 36247906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical